Navigation Links
Study finds tumor suppressor may actually fuel aggressive leukemia
Date:8/27/2013

CINCINNATI New research in the Journal of Clinical Investigation suggests that blocking a protein normally credited with suppressing leukemia may be a promising therapeutic strategy for an aggressive form of the disease called acute myeloid leukemia (AML).

Researchers from Cincinnati Children's Hospital Medical Center report their results in a study posted online Aug. 27 by the journal.

The protein scientists targeted is a transcription factor known as RUNX1, which also plays an important role in helping regulate the normal development of blood cells. The researchers were surprised to discover in their laboratory tests that RUNX1 was supporting the growth of AML fueled by what are called fusion proteins.

"RUNX1 is generally considered a tumor suppressor in myeloid neoplasms, but our study found that inhibiting its activity rather than enhancing it could be a promising therapeutic strategy for AMLs driven by fusion proteins," said James Mulloy PhD., a researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children's and lead investigator.

AML develops and progresses rapidly in patients, requiring prompt treatment with chemotherapy, radiation or bone marrow transplant. These treatments can be risky or only partially effective depending on the patient as well as the variation and progression of disease. Researchers like Mulloy are searching for improved treatment strategies, including targeted molecular approaches that could potentially be more effective and carry fewer side effects.

They tested this finding in a genetic mouse model of AML developed by Mulloy's laboratory that is driven by fusion proteins and a mixed-lineage leukemic gene called MLL-AF9. The researchers genetically inhibited both RUNX1 and an associated protein called core-binding factor subunit beta (Cbfb). By doing so, the researchers were able to stop the development of leukemia cells, demonstrating the potential viability of RUNX1 as a therapeutic target.

Also collaborating on the research was Paul Liu, MD, PhD, at the National Cancer Institute (National Institutes of Health), who developed a small molecule that specifically inhibits RUNX1. Using this inhibitor, the researchers showed that the AML cells were more sensitive than normal blood cells, indicating the inhibitor may be useful in the future as a therapy for patients with AML.

The research team continues to test inhibition of RUNX1 in AMLs driven by fusion proteins and in other blood disorders involving RUNX1. Their goal is to see how their findings might eventually lead to potential treatment of human disease.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Related medicine news :

1. African-American women less likely to receive HPV vaccine than whites, Pitt study finds
2. Kwiksure and MSIG Comment on Recent Study on the Use of Mobile Phones While Driving
3. Language can reveal the invisible, study shows
4. UCI, UCLA study reveals new approach to remedying childhood visual disorders
5. New Case Study From Orriant Demonstrates the Wellness Incentives That Come From a Healthy Lifestyle
6. Preschoolers who stutter do just fine emotionally and socially, study finds
7. Study supports intracerebral stem cell injections to prevent/reduce post-stroke cognitive deficits
8. Researchers from Mount Sinai receive NIH grant to study promising treatment for Autism subtype
9. Recent Kwiksure Study Suggests Expat Drivers in Hong Kong More Likely to Make Traffic Accident Claims Than Locals
10. Gallo Center study in mice links cocaine use to new brain structures
11. Study finds genomic differences in types of cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... A fifth-year speaker at the 2017 LBG Advisors Benefits Symposium , ... the state of the Affordable Care Act (ACA) with the new administration in place. ... hosted at Disney’s Grand Californian Hotel & Spa from February 26-28. It is designed ...
(Date:1/24/2017)... ... January 24, 2017 , ... The health ... Annual Enrollment Period (AEP) and the Open Enrollment Period (OEP). 2016 was no ... Mainly, people are witnessing higher deductibles, rising premiums, and few choices with their ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The Cruise ... Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... North American travel partners for the year based on overall business growth in revenue ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solutions, announced that it has officially formed a distribution partnership with Byers ... the industrial odor management industry. , Through the agreement, OMI Industries formulated a ...
(Date:1/24/2017)... Chapel Hill, N.C. (PRWEB) , ... January 24, ... ... the Trump Administration is the focus of a new report from the ... Carolina Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 2017  BioSpecifics Technologies Corp. (NASDAQ: ... originated and continues to develop collagenase based-therapies ... collagenase clostridium histolyticum, or CCH, marketed as ... ®  in Europe, today announced that BioSpecifics, President, Tom ... the upcoming NobleCon13 - Noble Capital Markets, ...
(Date:1/24/2017)... MOINES, Iowa , Jan. 24, 2017 When tragedy ... who the victim is, what conditions they have, and who back ... was created—to keep loved ones informed about the safety of their ... information they need about victims in times of crisis. ... If you find yourself or ...
(Date:1/24/2017)... PORTLAND, Oregon and PUNE, India ... A new report published by Allied Market Research, titled, ... Vegetables, Bakery & Confectionary, Dairy & Frozen Dessert, Meat, ... Industries): Global Opportunity Analysis and Industry Forecasts, 2014-2022," projects ... to garner $426,275 million by 2022, growing at a ...
Breaking Medicine Technology: